Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OncoCAIX
- Development stage
- Unknown
- Lead developer
- Philogen
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
OncoCAIX is a small molecule targeting agent developed by Philogen that specifically binds to Carbonic Anhydrase IX (CAIX), a cell-surface enzyme that is highly overexpressed in clear cell renal cell carcinoma (ccRCC) and other solid tumors under hypoxic conditions. As part of Philogen's 'Onco' platform of small molecule ligands, OncoCAIX is designed to deliver payloads, such as radionuclides for imaging (e.g., Gallium-68) or therapy (e.g., Lutetium-177), directly to the tumor site. This targeted approach aims to improve diagnostic accuracy and therapeutic efficacy while reducing systemic toxicity. The drug is currently in Phase 1 clinical trials for the treatment and imaging of patients with renal cell carcinoma.
- Other names
- CAIX-targeting small molecule
02
Targets
CA9 (Carbonic anhydrase IX)
Beyond the preview
Go deeper on OncoCAIX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OncoCAIX.